These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 28457754)
1. Investigation of the structural requirements of K-Ras(G12D) selective inhibitory peptide KRpep-2d using alanine scans and cysteine bridging. Niida A; Sasaki S; Yonemori K; Sameshima T; Yaguchi M; Asami T; Sakamoto K; Kamaura M Bioorg Med Chem Lett; 2017 Jun; 27(12):2757-2761. PubMed ID: 28457754 [TBL] [Abstract][Full Text] [Related]
2. K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology. Sakamoto K; Kamada Y; Sameshima T; Yaguchi M; Niida A; Sasaki S; Miwa M; Ohkubo S; Sakamoto JI; Kamaura M; Cho N; Tani A Biochem Biophys Res Commun; 2017 Mar; 484(3):605-611. PubMed ID: 28153726 [TBL] [Abstract][Full Text] [Related]
3. Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d. Sogabe S; Kamada Y; Miwa M; Niida A; Sameshima T; Kamaura M; Yonemori K; Sasaki S; Sakamoto JI; Sakamoto K ACS Med Chem Lett; 2017 Jul; 8(7):732-736. PubMed ID: 28740607 [TBL] [Abstract][Full Text] [Related]
4. Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo. Sakamoto K; Masutani T; Hirokawa T Sci Rep; 2020 Dec; 10(1):21671. PubMed ID: 33303890 [TBL] [Abstract][Full Text] [Related]
6. Substituted tetrahydroisoquinolines: synthesis, characterization, antitumor activity and other biological properties. Capilla AS; Soucek R; Grau L; Romero M; Rubio-MartÃnez J; Caignard DH; Pujol MD Eur J Med Chem; 2018 Feb; 145():51-63. PubMed ID: 29324343 [TBL] [Abstract][Full Text] [Related]
7. Discovery, optimization and biological activity evaluation of genipin derivatives as potential KRAS G12D inhibitors. Sun R; Hu Y; Liu X; Lin Y; Lv D; Li W; Fu L; Jiang F Bioorg Chem; 2024 Jul; 148():107460. PubMed ID: 38781668 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of new Myo-inositol derivatives as potential RAS inhibitors. Hussain J; Chhabria D; Kirubakaran S Bioorg Med Chem Lett; 2020 Aug; 30(16):127290. PubMed ID: 32631512 [TBL] [Abstract][Full Text] [Related]
9. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of novel substituted thiourea derivatives as potential anticancer agents for NSCLC by blocking K-Ras protein-effectors interactions. Zhang Y; Meng X; Tang H; Cheng M; Yang F; Xu W J Enzyme Inhib Med Chem; 2020 Dec; 35(1):344-353. PubMed ID: 31851852 [TBL] [Abstract][Full Text] [Related]
11. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640 [TBL] [Abstract][Full Text] [Related]
12. A PDX model combined with CD-DST assay to evaluate the antitumor properties of KRpep-2d and oxaliplatin in KRAS (G12D) mutant colorectal cancer. Li W; Chen W; Wang J; Zhao G; Chen L; Wan Y; Luo Q; Li W; Huang H; Li W; Li W; Yang Y; Chen D; Su Q Heliyon; 2022 Dec; 8(12):e12518. PubMed ID: 36590511 [TBL] [Abstract][Full Text] [Related]
13. Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant. Qin M; Wang T; Xu B; Ma Z; Jiang N; Xie H; Gong P; Zhao Y Eur J Med Chem; 2015 Nov; 104():115-26. PubMed ID: 26451770 [TBL] [Abstract][Full Text] [Related]
14. Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents. Li L; Zhao H; Liao H; Chen J; Liu J; Chen J Bioorg Chem; 2021 May; 110():104825. PubMed ID: 33774492 [TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship study of syringolin A as a potential anticancer agent. Chiba T; Matsuda A; Ichikawa S Bioorg Med Chem Lett; 2015 Nov; 25(21):4872-4877. PubMed ID: 26231162 [TBL] [Abstract][Full Text] [Related]
17. Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. Jose B; Oniki Y; Kato T; Nishino N; Sumida Y; Yoshida M Bioorg Med Chem Lett; 2004 Nov; 14(21):5343-6. PubMed ID: 15454224 [TBL] [Abstract][Full Text] [Related]
18. Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D). Palmioli A; Sacco E; Airoldi C; Di Nicolantonio F; D'Urzo A; Shirasawa S; Sasazuki T; Di Domizio A; De Gioia L; Martegani E; Bardelli A; Peri F; Vanoni M Biochem Biophys Res Commun; 2009 Sep; 386(4):593-7. PubMed ID: 19540195 [TBL] [Abstract][Full Text] [Related]